Weight LossMetabolicFDA Approved

Tirzepatide

Dual GIP/GLP-1 agonist

Next-gen dual agonist (Mounjaro/Zepbound).

⚡ Fat Loss

Mechanism of Action

Dual GIP + GLP-1 agonism.

Key Benefits

Up to 20%+ weight loss

Common Uses

Severe obesity

What to Expect

Onset

Appetite suppression within 24–48 hours; many report it feeling 'stronger' than semaglutide from the start

Duration

~7 days per injection; dual mechanism provides more sustained energy and satiety

What Users Report

Potent appetite suppression — often described as stronger and more comprehensive than semaglutide alone
More sustained and stable energy levels throughout the day, attributed to the GIP component
Less nausea than semaglutide for some users, though GI effects still occur during titration
Rapid and significant weight loss — many report faster results than with GLP-1-only drugs
Improved blood sugar stability; reduced energy crashes and afternoon slumps
Feeling 'too full' if attempting normal-sized portions — must consciously eat smaller meals
Some users report improved mood and mental clarity as metabolic health improves

Typical Timeline

Days 1–2: Appetite noticeably reduced. Weeks 1–4: Titration phase — GI side effects possible but often less severe than semaglutide. Weeks 4–8: Accelerated weight loss; many report faster progress than GLP-1-only therapy. Months 2–6: 20%+ total body weight loss is achievable at higher doses. Ongoing: Sustained metabolic improvements with continued use.